VODG Stock UPDATES Vitro Diagnostics (VODG) 0.1700 08/11/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Vitro Diagnostics (VODG) 0.1700 $VODG

Frost & Sullivan Honors Vitro Biopharma for its Outstanding Technological Innovations and Business Strategy in the Stem Cell Tools Industry
PR Newswire Europe - Tue Aug 05, 7:46AM CDT
--The company aims to increase the market penetration of its proprietary MSC-based research products, while expanding its stem cell segment to include differentiated cells derived from MSCs

Vitro Biopharma Receives Frost & Sullivan Technology Innovation Leadership Award: 2014 Best Practices for Stem Cell Tools & Technology in North America
ACCESSWIRE - Wed Jul 09, 11:00AM CDT
Golden, CO / ACCESSWIRE / July 9, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, is pleased to announce receipt of a prestigious award from Frost & Sullivan. The award is based on independent analysis of competing companies' commitment to innovation, commercial success, application diversity and fulfillment of unmet needs. Vitro Biopharma out-ranked competing firms in all areas evaluated.

Vitro Biopharma Announces Advances in Stem Cell Therapy without Transplants
ACCESSWIRE - Tue Jun 10, 8:34AM CDT
Golden, Colorado / ACCESSWIRE / June 10, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, has been pursuing the determination of therapeutic benefits derived from activation of adult stems residing within the human body. This approach is advantageous over transplantation since many of the complications are overcome including, effects of in-vitro stem cell expansion, effects of allogeneic cells and regulatory obstacles. Recent research has validated and expanded the scope of this approach by reports of increased muscle performance & endurance as well as reported changes critical learning periods that may be due to activation of neural stem cells in the adult brain. It is thus likely that activation of adult stem cells leads to specific performance enhancement as is well-known for activation of blood (hematopoietic) stem cells by growth factors that stimulate generation of red or white blood cells. We have published 2 new blogs providing more detail regarding stem cell therapy without transplants http://vitrobiopharma.com/2014/06/06/stem-cel...nt-status/.

Vitro Biopharma Products Advance Pancreatic Cancer Research
ACCESSWIRE - Tue Mar 11, 9:08AM CDT
Golden, Colorado / ACCESSWIRE / March 11, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced that some of its products are being utilized in advancing pancreatic cancer research including development of new diagnostic tests and new therapeutic approaches. Pancreatic cancer remains one of the most deadly and least survivable cancers; it is asymptomatic until quite advanced and is resistant to conventional therapies. It has recently become apparent that cancer tumor cells are closely associated with other cells called cancer associated fibroblasts or CAFs. These cells promote the malignant process and block immune surveillance. CAFs are thus new drug targets for pancreatic and other cancer therapies. Vitro Biopharma products were used in recent research regarding pancreatic stellate cells, a CAF that is gaining considerable interest for new treatment options through advanced understanding of cancer biology.

10-K: VITRO DIAGNOSTICS INC
Edgar Online - Wed Feb 12, 3:26PM CST
ITEM 7.

Vitro Biopharma Revenues Increase in Early 2014: Plans Trials of Endogenous Stem Cell Activation for Therapeutic Benefit
ACCESSWIRE - Tue Feb 11, 9:19AM CST
Golden, Colorado / February 11, 2013 / ACCESSWIRE / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced that its revenues increased substantially (78%, unaudited) in its first 2014 fiscal quarter due to its growing and expanding business relationship with Neuromics, Inc. Vitro Biopharma has now commercialized bio-analytical services as the initial stage in its expansion as a Contract Research Organization (CRO). The services now available include select and customized biomarker panel analysis providing customers quantitative levels of multiple biological molecules within various biological samples. The new business involves analysis of human serum samples collected from patients within a network of clinical treatment centers throughout central Europe. Our partner for these services is Joseph Smarta, Ph.D., a renowned immunologist who has orchestrated treatment of many patients suffering from a variety of diseases. While the analyses are for research purposes only, serial analysis of patients are provided to monitor status and indicate therapeutic effectiveness.

Vitro Biopharma Expands its Product Lines While Targeting New Stem Cell Markets
ACCESSWIRE - Tue Sep 10, 7:00AM CDT
Golden, Colorado - (ACCESSWIRE - September 10, 2013) - Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced expansion of its current product lines and product development in additional market segments including drug discovery & development together with select opportunities within regenerative medicine market sectors. Vitro's present products target markets within stem cell and cancer research. We provide basic research tools including cell lines, cell culture media and assays of cellular function. We have recently added cancer-associated fibroblast cell lines and novel cell culture media formulations broadening our product offerings for research. Cancer-associated fibroblasts (CAFs) are non-tumor cells within cancerous tumors that promote tumor growth and metastasis.

OTC Daily Alert Stock Watch - Vitro Diagnostics, Inc. (OTCQB: VODG)
WorldStockWire - Thu Aug 29, 3:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Vitro Biopharma Appoints Established Life Science Sales Executive to Its Board of Directors
GlobeNewswire - Wed Feb 20, 12:25PM CST
Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma, simultaneously accepted the resignation of Mr. Erik Van Horn from its Board of Directors and appointed Pete Shuster, the CEO of Neuromics, Inc. to its Board of Directors. Mr. Shuster is a seasoned and experienced sales executive. He is the current owner of Neuromics, Inc., a privately held and profitable business focused on sales of numerous (>2500) specialty life science products including stem cell products manufactured by Vitro Biopharma. Neuromics, Inc. sales have grown over 5.5-fold since inception in 2003. Shuster has extensive prior experience in managing sales of computer software and related products for companies including Caterpillar, Baxter Healthcare and Harley-Davidson.

Vitro Biopharma Inc announces commercial availability of MSC-derived human osteoblasts, leading to faster recovery of bone fractures
M2 - Wed Jan 23, 10:44AM CST
Stem cell company Vitro Diagnostics Inc (OTCQB:VODG) said on Tuesday that it has introduced a series of osteoblasts products to accelerate bone growth, fracture healing and development of new osteoporosis drugs.

Vitro Biopharma Launches New Stem Cell Products to Accelerate Bone Growth
GlobeNewswire - Tue Jan 22, 8:51AM CST
Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma, announced the launch of a series of products with application to accelerated bone growth, fracture healing and development of new osteoporosis drugs. The new products are osteoblasts derived from human adult stem cells known as mesenchymal stem cells (MSCs). These cells lead to bone growth and function to maintain bone density and in the recovery from bone fractures. Osteoporosis, a disease characterized by reduction in bone density is thought to result from decreased osteoblast production by MSCs; bone growth necessary for repair of bone fractures also depends on osteoblasts. The new products include native and labeled MSC-derived human osteoblasts in various formats including fluorescent and magnetic cells for use in different imaging methods. For example, magnetic osteoblast cells labeled with super paramagnetic iron oxide (SPIO) may be used for in-vivo imaging of osteoblasts using magnetic resonance imaging (MRI) a common clinical imaging proced




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Swell Partners' Awards Highlight Culture, Not Metrics

Updated Category News Views 65

Recognition Lands in a Crowded Talent Market Two shiny Stevie trophies do not pay payroll, but they can say something useful about a company trying to stand out in the noisy talent-services business. Swell Partners has been named 2026 Company of the Year in Business Services and has seen founder and CEO Cari Gatto receive Best Female CEO of the Year. For a private firm...

Continue Reading
A. O. Smith's Sustainability Scorecard Has Real Teeth

Updated Category News Views 40

Numbers finally showed up wearing work boots in A. O. Smith’s latest sustainability report. The company says it beat every one of its three environmental targets, and the gaps were not the sort of rounding-error victories corporate communications teams love to polish until they shine. For investors following NYSE:AOS, that deserves a look—not a standing ovation, but a...

Continue Reading
Scientific Games Takes Big Buck Hunter to Lotteries

Updated Category News Views 33

A mounted arcade cabinet is an odd place to find lottery growth, yet Scientific Games may be onto something with its exclusive Big Buck Hunter licensing deal. Announced November 19, 2026, the arrangement lets the company carry a 26-year-old arcade franchise into U.S. and Canadian instant scratch games, Fast Play, draw games, digital products and second-chance promotions....

Continue Reading
Peñoles Locks In Solar Storage for Northern Mine Loads

Updated Category News Views 159

A mine never sleeps, which is why the battery matters more than the solar-panel headline. Peñoles has signed a 20-year power-supply agreement with Atlas Renewable Energy for a Coahuila project combining 269 MWp of solar generation with battery storage. The project is slated to begin operating in the first half of 2029 and is expected to provide roughly 550 GWh a year to...

Continue Reading
Pennsylvania Rebate Rules Matter Before Year-End Filing

Updated Category News Views 47

A missed rebate form can sting harder than most people expect, especially when a household has already spent the year watching property taxes, rent, groceries, and every other stubborn bill chew through fixed income. Pennsylvania’s Property Tax/Rent Rebate Program is not glamorous, and it is certainly not an investing story. It is, however, the kind of direct household...

Continue Reading
RMT’s 12.4% Discount Still Demands a Much Harder Look

Updated Category News Views 23

A $1.84 gap is staring RMT shareholders right in the face. As of October 31, 2026, Royce Micro-Cap Trust carried a net asset value of $14.82 per share while the market price sat at $12.98. That is roughly a 12.4% discount to NAV, and closed-end fund investors should never wave off a spread like that with a lazy shrug. It may be opportunity. It may also be the market...

Continue Reading
Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 104

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 116

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading
PARRIS Partners Earn 2026 Plaintiff Lawyer Recognition

Updated Category News Views 95

A $58.4 million jury number can make a courtroom sound like a slot machine, until the final settlement lands at $21 million. That gap is the part people ought to stare at before getting carried away by another plaintiff-lawyer honor roll. The Daily Journal has named PARRIS Law Firm partners Alexander R. Wheeler and Khail A. Parris to its 2026 Top Plaintiff Lawyers special...

Continue Reading
Dubai's 2028 Fire Congress Puts Global Safety Tech on Stage

Updated Category News Views 77

Fire engines, wildfires, dense towers, and AI are all colliding in Dubai's next big public-safety moment. The World Fire Congress has handed its 2028 host role to Dubai, making this the first time the biennial gathering of global fire and emergency-service leaders will land in the Middle East. That is not a quarterly earnings event, and nobody ought to pretend it is....

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Urged to Review iRobot Class Action Details Amid Losses

Updated Category News Views 180

Class Action Lawsuit Against iRobot: What Investors Need to Know Bragar Eagel & Squire, P.C., an established law firm known for representing investors, is currently addressing losses incurred by shareholders of iRobot Corporation (IRBT). The firm is encouraging affected investors to reach out and discuss their legal options moving forward. Details of the Class Action...

Continue Reading
Customer Loyalty Solutions Market Poised for Significant Growth

Updated Category News Views 223

Customer Loyalty Solutions Market Poised for Significant Growth Recently, a leading market intelligence firm has conducted a comprehensive analysis of the global Customer Loyalty Solutions (CLS) Market, revealing a promising trajectory toward a compound annual growth rate (CAGR) of 11.8% projected through 2030. This analysis aims to provide companies with the strategic...

Continue Reading
Armada Hoffler Properties Reports Strong Q4 Earnings Growth

Updated Category News Views 218

Armada Hoffler Properties Highlights Strong Fourth Quarter Performance Armada Hoffler Properties, Inc. (NYSE: AHH) recently shared its financial results for the fourth quarter of the fiscal year. This announcement underscored the company's robust performance, demonstrating a commitment to growth and stability. Key Financial Metrics The company reported a net income of...

Continue Reading
Hillman Solutions Corp. Earnings Call Scheduled for November

Updated Category News Views 143

Hillman Solutions Corp. Announces Earnings Conference Call Hillman Solutions Corp. (NASDAQ: HLMN), a recognized leader in providing hardware and merchandising solutions, has scheduled a conference call to review its financial results for the thirteen and thirty-nine weeks ending September 27, 2025. This much-anticipated call will take place on November 4, starting at 8:30...

Continue Reading
Investigation Initiated into Abacus Global Management, Inc.

Updated Category News Views 428

Investigation Initiated into Abacus Global Management, Inc. Robbins Geller Rudman & Dowd LLP is spearheading an investigation into potential violations of U.S. federal securities laws concerning Abacus Global Management, Inc. (NASDAQ: ABL). The focus of this inquiry revolves around whether the company and some of its key executives delivered misleading statements or...

Continue Reading